180 Wealth Advisors’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $998K | Sell |
20,826
-1,199
| -5% | -$51.5K | 0.1% | 203 |
|
|
2026
Q1 | $809K | Buy |
22,025
+4,713
| +27% | +$223K | 0.09% | 216 |
|
|
2025
Q4 | $881K | Buy |
17,312
+4,363
| +34% | +$223K | 0.1% | 199 |
|
|
2025
Q3 | $719K | Buy |
12,949
+7,457
| +136% | +$436K | 0.09% | 210 |
|
|
2025
Q2 | $379K | Buy |
5,492
+478
| +10% | +$32.5K | 0.05% | 290 |
|
|
2025
Q1 | $348K | Buy |
5,014
+173
| +4% | +$14.3K | 0.06% | 289 |
|
|
2024
Q4 | $416K | Buy |
4,841
+36
| +0.7% | +$3.89K | 0.07% | 256 |
|
|
2024
Q3 | $572K | Sell |
4,805
-38
| -0.8% | -$5.07K | 0.09% | 206 |
|
|
2024
Q2 | $677K | Sell |
4,843
-1,706
| -26% | -$226K | 0.11% | 170 |
|
|
2024
Q1 | $841K | Buy |
6,549
+223
| +4% | +$26.5K | 0.15% | 143 |
|
|
2023
Q4 | $646K | Sell |
6,326
-174
| -3% | -$17.2K | 0.13% | 163 |
|
|
2023
Q3 | $591K | Buy |
6,500
+722
| +12% | +$63.6K | 0.13% | 160 |
|
|
2023
Q2 | $461K | Sell |
5,778
-3,032
| -34% | -$248K | 0.1% | 202 |
|
|
2023
Q1 | $701K | Sell |
8,810
-160
| -2% | -$11.3K | 0.16% | 143 |
|
|
2022
Q4 | $617K | Sell |
8,970
-738
| -8% | -$43.3K | 0.15% | 146 |
|
|
2022
Q3 | $484K | Sell |
9,708
-928
| -9% | -$49.7K | 0.13% | 149 |
|
|
2022
Q2 | $594K | Sell |
10,636
-148
| -1% | -$8.21K | 0.15% | 130 |
|
|
2022
Q1 | $617K | Sell |
10,784
-126
| -1% | -$6.47K | 0.13% | 148 |
|
|
2021
Q4 | $520K | Sell |
10,910
-1,306
| -11% | -$70.8K | 0.12% | 167 |
|
|
2021
Q3 | $625K | Hold |
12,216
| – | – | 0.14% | 143 |
|
|
2021
Q2 | $611K | Sell |
12,216
-398
| -3% | -$15.4K | 0.14% | 144 |
|
|
2021
Q1 | $513K | Sell |
12,614
-496
| -4% | -$17.7K | 0.13% | 161 |
|
|
2020
Q4 | $479K | Sell |
13,110
-48
| -0.4% | -$1.66K | 0.14% | 152 |
|
|
2020
Q3 | $469K | Buy |
13,158
+3,848
| +41% | +$128K | 0.18% | 121 |
|
|
2020
Q2 | $313K | Sell |
9,310
-888
| -9% | -$28.3K | 0.12% | 169 |
|
|
2020
Q1 | $302K | Sell |
10,198
-200
| -2% | -$5.96K | 0.16% | 153 |
|
|
2019
Q4 | $324K | Buy |
10,398
+1,094
| +12% | +$30.3K | 0.13% | 189 |
|
|
2019
Q3 | $238K | Buy |
+9,304
| New | +$235K | 0.11% | 220 |
|
|
2019
Q1 | – | Sell |
-8,588
| Closed | -$202K | – | 271 |
|
|
2018
Q4 | $202K | Hold |
8,588
| – | – | 0.09% | 240 |
|
|
2018
Q3 | $202K | Sell |
8,588
-744
| -8% | -$18.2K | 0.09% | 240 |
|
|
2018
Q2 | $215K | Buy |
+9,332
| New | +$222K | 0.11% | 221 |
|
Other funds holding NVO
F
180 Wealth Advisors's NVO Position: Q2 2026 in Review
180 Wealth Advisors reduced its Novo Nordisk (NVO) stake by 5.4% in Q2 2026, selling an estimated $51.5K and leaving 20,826 shares worth $998K. The position accounts for 0.1% of the portfolio, ranked #203.
180 Wealth Advisors first reported a position in NVO in Q2 2018 and has held it in 31 quarters since. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.
- 180 Wealth Advisors held 20,826 shares of Novo Nordisk worth $998K as of Q2 2026.
- 180 Wealth Advisors sold 1,199 Novo Nordisk shares in Q2 2026, an estimated $51.5K.
- Novo Nordisk made up 0.1% of 180 Wealth Advisors's portfolio in Q2 2026, its #203 holding.
- 180 Wealth Advisors first reported a position in Novo Nordisk in Q2 2018 and has held it in 31 quarters since.
- 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.
Based on 180 Wealth Advisors's 13F filing for Q2 2026, filed 7 Jul 2026.